about us


Paradigm Biopharma (PAR) listed on the ASX in August 2015. We focus on repurposing pentosan polysulphate sodium (PPS) for new orthopaedic and respiratory applications. We address conditions that start with and are sustained by inflammation. Lead clinical indications involve treating injury that results in bone marrow edema (BME) and the allergic inflammatory response in allergic rhinitis (AR), which is commonly known as ‘Hay Fever’.


about us


Paradigm Biopharma (PAR) listed on the ASX in August 2015. We focus on repurposing pentosan polysulphate sodium (PPS) for new orthopaedic and respiratory applications. We address conditions that start with and are sustained by inflammation. Lead clinical indications involve treating injury that results in bone marrow edema (BME) and the allergic inflammatory response in allergic rhinitis (AR), which is commonly known as ‘Hay Fever’.

Repurposing PPS


The cost and complexity of starting with a new molecule, led us to explore the possibility of finding a simpler path to treating complex disease. This led us to explore repurposing PPS, an FDA approved drug that has a long track record of treating inflammation, but which had been used narrowly to treat bladder inflammation (interstitial cystitis) and for preventing deep vein thrombosis.

By working closely with the proprietary manufacturer of PPS, we are able to leverage substantial knowledge and expertise available from earlier regulatory filings. This involves decades of accumulated toxicology safety data, formulation know how, and extensive published information about PPS’s mode of action, which primarily involves modulation of proteins impacting inflammation. With this foundation, Paradigm Biopharma minimises its risk profile as an early stage drug development company. We already see shortened drug development cycle time for our chosen applications and development costs minimised.

Experienced multidisciplinary team


We have a focused, multidisciplinary management team with broad fundamental experience of complex diseases and networked pathways, and special emphasis on inflammation and regenerative medicine. We also have deep knowledge of taking drugs through clinical trials and structuring deals with small and large corporations.

Our model is to outsource significant aspects of clinical development and use the executive team to manage this process. Our board has deep experience of the international biotech scene, including bringing new drugs to market, as well as high level partnering and deal making skills.